Roivant says FDA approves LISRAYA for adults with dermatomyositis

Reuters2026/08/27 19:29

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Roivant won FDA clearance for LISRAYA (brepocitinib) 30 mg to treat adults with dermatomyositis in the U.S.
Launch starts immediately; product positioned as a once-daily oral TYK2/JAK1 inhibitor, first targeted therapy cleared for the disease.
Approval based on the Phase 3 VALOR trial; 55% reached moderate-or-better improvement with minimal or no steroid use at week 52.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608271529PRIMZONEFULLFEED9817373) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Roivant says FDA approves LISRAYA for adults with dermatomyositis

You may also like

Crypto prices